June 12, 2017 8:59am

FCSC is up +$0.23 or +9.27% in the pre-market, it's a BUY with an exit defined in short timing ... news has a life cycle in this market



Fibrocell Science said … the  FDA granted rare pediatric disease designation to FCX-013, a gene therapy candidate to treat localized scleroderma.


The Bottom Line: Boom in news and bust – dribbles out over time as drug is being developed in collaboration with Intrexon (XON. FCSC is submitting investigational new drug application (IND) for FCX-013 to the FDA in 4Q 2017 – still VERY early